Eli Lilly and Company 10-Qquarter ended 2026-06-30

Executive Summary

Eli Lilly’s Q2 2026 growth was driven by Mounjaro and Zepbound volume, especially outside the U.S., even as lower realized prices offset part of the gain. Revenue rose 48% Y/Y, while acquisition-related research charges, integration costs and higher taxes held net income growth to 25%. Operating cash flow funded substantial manufacturing investment, but acquisitions and shareholder returns also increased debt and reduced tangible common equity. For investors, the opportunity is a broader obesity portfolio and international reach; the key test is whether volume growth and new launches can sustain returns as pricing pressure and capital commitments rise.

Key Financial Highlights

• Revenue mix: Mounjaro and Zepbound generated 65% of H1 revenue. Consolidated Q2 volume growth of 60% was partly offset by a 13% price drag; revenue outside the U.S. grew 80%, faster than U.S. revenue at 33%.
• Spending: Q2 research and development was $3.82B, +14% Y/Y. Acquired in-process research and development charges reached $2.78B in Q2 and $3.36B in H1; special charges added $703M and $982M, respectively. These costs distinguish investment and deal-related expense from underlying sales momentum.
• Cash conversion and capital returns: H1 OCF rose from $4.75B a year earlier to $16.0B, exceeding H1 net income of $14.5B; FCF was $10.8B after higher manufacturing capital expenditures. Lilly repurchased 4.4M shares for $3.98B, while shares outstanding fell only 3.3M, from 944.8M to 941.5M; stock-based compensation was $362M.

Business Developments

Lilly is extending its cardiometabolic franchise across products, markets and access channels. Q2 Mounjaro revenue reached $9.94B, +91% Y/Y, and Zepbound reached $4.93B, +46%; Mounjaro revenue outside the U.S. reached $5.2B, versus $1.9B a year earlier. Management is expanding manufacturing capacity to support demand, with meaningfully higher capital expenditures expected near term.

The U.S. launch of oral obesity medicine Foundayo in Q2 adds a potential growth channel beyond injectable treatments. Lilly also submitted it for type 2 diabetes in the U.S., Europe and Japan; Phase 3 retatrutide trials met primary endpoints. These developments offer a path to broaden the franchise, but their contribution depends on approvals, uptake and competitive differentiation.

Business development is diversifying the pipeline at significant upfront cost. H1 acquisition-date consideration for Kelonia, Centessa and Ventyx totaled $12.7B; Lilly also incurred charges for acquired research programs. After quarter-end, it paid ≈$2.0B for three infectious-disease acquisitions, with potential aggregate consideration of up to $3.9B. Management’s stated approach is to allocate research spending by commercial and technical prospects; the inferred trade-off is greater pipeline breadth alongside higher funding needs and contingent payments.

Risk Assessment

• Product concentration and access: Mounjaro and Zepbound supplied 65% of H1 revenue, exposing growth to incretin demand, supply, payer coverage, competition and channel mix.
• Pricing pressure: A 13% Q2 price drag offset volume gains; government pricing, cash-pay reductions and reimbursement changes could limit how much demand growth reaches revenue.
• Capital intensity and acquisition execution: Total debt increased $12.4B to $54.9B, while manufacturing expansion, integration spending and contingent consideration liabilities of $2.52B add demands on future cash generation.
• Litigation and intellectual property: Incretin product-liability claims, pricing and 340B disputes, and potential generic challenges could materially affect an individual period’s earnings; maximum exposure cannot be estimated for many proceedings.
• Regulatory and product integrity: Manufacturing quality requirements and counterfeit or mass-compounded incretins pose safety, enforcement and commercial risks to the expanding franchise.
• Tax uncertainty: Unresolved examinations and an intercompany-pricing dispute could affect future tax outcomes, while nondeductible acquired research charges helped lift the Q2 effective tax rate to 23.3% from 16.5%.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

The near-term thesis rests on converting incretin demand and new product access into profitable, cash-generating growth while absorbing capacity spending and acquisitions. The Medicare obesity-medicine Bridge Program runs from 7/1/2026 through 12/31/2027, but uptake and access beyond it remain uncertain.

• Monitor volume versus realized price: Sustained volume growth exceeding the Q2 13% price drag would support continued revenue expansion; a narrowing gap would challenge it.
• Monitor Foundayo uptake and international Mounjaro sales: Growth beyond H1 Mounjaro revenue outside the U.S. of $9.58B would show whether the franchise is broadening its growth base.
• Monitor OCF, capital expenditures and debt: Cash generation covering investment and acquisition commitments without continued material debt growth would strengthen the capital-allocation case.